Literature DB >> 7513541

Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p.

M H Jones1, S Koi, I Fujimoto, K Hasumi, K Kato, Y Nakamura.   

Abstract

Cancers in which mutations have been identified in putative tumor suppressor genes, such as the TP53 gene, the retinoblastoma (RBI) gene, the adenomatous polyposis coli (APC) gene, and the Wilms tumor (WTI) gene, frequently show loss of the corresponding allele on the homologous chromosome. To identify locations of tumor suppressor genes involved in uterine cancer, we examined loss of heterozygosity (LOH) by using genomic probes detecting RFLPs in 35 uterine cancers at 29 loci throughout the genome, and with highly informative microsatellite markers in 21 uterine cancers at nine putative or known tumor suppressor gene loci. High frequencies of allelic loss found at loci on 3p (71%), 9q (38%), 10q (35%), and 17p (35%) suggest that tumor suppressor genes involved in uterine carcinogenesis exist in these regions. There were no significant differences in frequencies of LOH between cancers of the uterine cervix and cancers of the uterine endometrium at any of the loci tested.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513541     DOI: 10.1002/gcc.2870090207

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

1.  Allelic loss at TP53 in metastatic human endometrial carcinomas.

Authors:  Wiktor Szewczuk; Danuta Skomra; Marek Cybulski; Dorota Przadka-Rabaniuk; Agata Filip; Maciej Jóźwik; Piotr Olcha; Albert Roessner; Andrzej Semczuk
Journal:  Clin Exp Metastasis       Date:  2009-06-30       Impact factor: 5.150

Review 2.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

3.  A strategy for constructing high-resolution genetic maps of the human genome: a genetic map of chromosome 17p, ordered with meiotic breakpoint-mapping panels.

Authors:  S C Gerken; H Albertsen; T Elsner; L Ballard; P Holik; E Lawrence; M Moore; X Zhao; R White
Journal:  Am J Hum Genet       Date:  1995-02       Impact factor: 11.025

4.  Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from Northern Indian population.

Authors:  M Moshahid Alam Rizvi; M Shabbir Alam; Syed Jafar Mehdi; Asgar Ali; Swaraj Batra
Journal:  Pathol Oncol Res       Date:  2011-09-08       Impact factor: 3.201

5.  Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis.

Authors:  E D Lynch; E A Ostermeyer; M K Lee; J F Arena; H Ji; J Dann; K Swisshelm; D Suchard; P M MacLeod; S Kvinnsland; B T Gjertsen; K Heimdal; H Lubs; P Møller; M C King
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

6.  Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11.

Authors:  W H Raskind; E U Conrad; H Chansky; M Matsushita
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

Review 7.  Molecular events in uterine cervical cancer.

Authors:  S A Southern; C S Herrington
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

8.  G protein-coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of human colon cancer cells.

Authors:  Chang-Chieh Wu; Fu-Ming Tsai; Rong-Yaun Shyu; Ya-Ming Tsai; Chun-Hua Wang; Shun-Yuan Jiang
Journal:  BMC Cancer       Date:  2011-05-17       Impact factor: 4.430

9.  Deletion mapping on chromosome 10q25-q26 in human endometrial cancer.

Authors:  S Nagase; S Sato; F Tezuka; Y Wada; A Yajima; A Horii
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

10.  beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.

Authors:  M Saegusa; M Hashimura; T Yoshida; I Okayasu
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.